NeoGenomics Announces Commercial Availability of the RaDaR(R) Molecular Residual Disease Test Mar 16, 2023
NeoGenomics Expands NGS Portfolio with Launch of Neo Comprehensive(TM) - Solid Tumor CGP and Neo Comprehensive(TM) - Myeloid Disorders CGP Mar 13, 2023
NeoGenomics to Present at the 44th Annual Raymond James Institutional Investors Conference Feb 28, 2023
NeoGenomics Schedules its Fourth Quarter and Full Year 2022 Earnings Release for February 23, 2023 Feb 6, 2023
RaDaR® Assay Demonstrates Clinical Potential for Helping Oncologists Determine Whether or Not Muscle-Invasive Bladder Cancer Patients Undergo Radical Surgery Feb 6, 2023
RaDaR(R) Assay Demonstrates Clinical Potential for Detecting Disease Recurrence Across All Types of Early Breast Cancer, Including Triple Negative Disease Nov 21, 2022
